Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968708 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,380
- Enrollment target
NCT00968708: Completed Phase 3 study, sponsored by Takeda.
NCT00968708 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 5,380 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (597% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00968708, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,380 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
Primary Outcome
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.
Interventions
- DRUG Placebo
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,380 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT00968708 record still lists
NCT00968708 is an interventional study that assigns participants to a tested intervention. Its 5,380 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (597% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00968708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00968708 about?
NCT00968708 is a clinical study titled "Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome". The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
What is the current status of trial NCT00968708?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,380 participants. The study started on 2009-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00968708?
The interventions under investigation include: Placebo (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00968708?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00968708's enrollment target sits among peer trials
5,380 45th of 2000 higher than 1,956 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia